Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 236 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Buprenorphine/Naloxone Clear all

Conditions: Opioid Dependence, on Agonist Therapy
Interventions: Higher bioavailability BNX sublingual tablets; Drug
Lead sponsor: Orexo AB; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 28
States / cities: Jefferson County, Alabama • Marion County, Alabama • Winston County, Alabama + 25 more

Conditions: Opioid Use Disorder (OUD)
Interventions: SL-BUP, XR-BUP, XR-NTX, MM, MMR, MMD; Drug · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 1,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 21
States / cities: Little Rock, Arkansas • Tarzana, California • Bridgeport, Connecticut + 17 more

Conditions: Opioid Use Disorder
Interventions: buprenorphine; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 41 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Maternal Opioid Use Disorder, Opioid Exposed Infant
Interventions: fetal monitoring, Buprenorphine Naloxone; Device · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opioid-use Disorder
Interventions: Buprenorphine Naloxone; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions: Buprenorphine Injection, Buprenorphine Sublingual Product; Drug
Lead sponsor: T. John Winhusen, PhD; Other
Eligibility: Not listed
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Jacksonville, Florida • Boston, Massachusetts • Portland, Oregon + 6 more

Conditions: Healthy Volunteer, Opioid-use Disorder
Interventions: INDV-2000, Placebo, SUBOXONE® sublingual film; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas

Conditions: Opioid Use Disorder
Interventions: Buprenorphine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Oakland, California • San Leandro, California • Portland, Maine + 2 more

Conditions: Opioid Abuse
Interventions: Implementation of the BINDeR-Tx service model; Behavioral
Lead sponsor: Jerry Cochran; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Opioid Dependency
Interventions: Probuphine (buprenorphine implant), placebo implant, Buprenorphine; Drug
Lead sponsor: Titan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Los Angeles, California • National City, California • Oceanside, California + 16 more

Conditions: Opiate Dependency Relapse
Interventions: Not listed
Lead sponsor: Care Team Solutions; Industry
Eligibility: 21 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Opiate Dependence
Interventions: Buprenorphine/Subutex, Naltrexone, Drug counseling; Drug · Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Opioid Addiction
Interventions: FMRI, Suboxone; Other · Drug
Lead sponsor: Butler Hospital; Other
Eligibility: 21 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Opioid Use Disorder
Interventions: RBP-6000, SUBOXONE Sublingual Film; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Opioid Dependency
Interventions: Psychosocial treatment plus Suboxone pharmacotherapy; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 15 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid-use Disorder
Interventions: XR-B (SUBLOCADETM), XR-NTX; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: New Haven, Connecticut • Baltimore, Maryland • Hanover, New Hampshire + 3 more

Conditions: Hepatitis C, Heroin Dependence
Interventions: Buprenorphine/naloxone, pegInterferon; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Oakland, California

Conditions: Heroin Dependence, Opioid-Related Disorders
Interventions: Opioid-Related Disorders; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Opioid Use Disorder, Opioid Use, Opioid Abuse, Opioid Misuse, Opioid Dependence
Interventions: buprenorphine/naloxone; Drug
Lead sponsor: Bicycle Health; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Buprenorphine / Naloxone; Drug
Lead sponsor: NanoSHIFT LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Drug Overdose, Opioid Withdrawal, Opioid-use Disorder
Interventions: Buprenorphine; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Heroin Dependence, Opioid-Related Disorders
Interventions: Opioid-Related Disorders; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
Interventions: Buprenorphine/naloxone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 15 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 7
States / cities: Berkeley, California • Oxnard, California • Indianapolis, Indiana + 4 more

Conditions: Opioid Dependency
Interventions: Probuphine (buprenorphine implant); Drug
Lead sponsor: Titan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: North Miami, Florida

Search by objective public record fields.

Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women

Maternal Buprenorphine-naloxone Treatment and the Infant

Buprenorphine Loading in the Emergency Department

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

Standard Versus High Dose ED-Initiated Buprenorphine Induction

Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment

A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction

Using mHealth to Aid Opioid Addicts

HIV Risk Reduction and Drug Abuse Treatment in Malaysia

Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

Optimizing Outcomes Using Suboxone for Opiate Dependence

Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

Novel Induction to Buprenorphine/Naloxone

A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone

Feasibility of the Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid Withdrawal

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3

Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1

Study of Probuphine in Patients With Opioid Dependence